Focused On-demand Library for Ras-related protein Rab-26

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9ULW5

UPID:

RAB26_HUMAN

Alternative names:

Alternative UPACC:

Q9ULW5; B2RAA6; Q3L6K5; Q6NXS7

Background:

Ras-related protein Rab-26 plays a pivotal role in intracellular membrane trafficking, regulating the transport of specific receptors and enzymes to their designated locations within the cell. It orchestrates the journey of vesicles from their formation to their fusion with membranes, ensuring the precise delivery of cargo such as ADRA2A and ADRA2B to the cell membrane, and facilitating the secretion of digestive enzymes in the stomach and salivary glands.

Therapeutic significance:

Understanding the role of Ras-related protein Rab-26 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes highlights its potential as a target for modulating disease mechanisms related to vesicle trafficking and secretion.